RxDoctor Payments Data

Carlos Rodriguez-Mendoza, MD

Internal Medicine · Bradenton, FLNPI 1245225077

Payments from drug & device makers

$1,272in general payments, 2019–2025

Across 29 payments — averaging $43.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Silk Road Medical, Inc.$553
  • AstraZeneca$318
  • Pfizer$109
  • Boehringer Ingelheim$66
  • Astellas Pharma US Inc$48
  • Boston Scientific$30
  • plus $147 from 7 others

What the payments were for

  • Travel & lodging$37329%
  • Food & beverage$89971%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,272 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$310,080
Medicare patients
993
Services billed
7,245

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide132$165,293
OzempicSemaglutide70$71,071
EliquisApixaban50$63,920
JardianceEmpagliflozin35$44,961
Breztri AerosphereBudesonide/Glycopyr/Formoterol38$34,753
XareltoRivaroxaban19$27,839
FarxigaDapagliflozin Propanediol21$22,671
TrulicityDulaglutide11$22,100
RybelsusSemaglutide11$18,502
JanuviaSitagliptin Phosphate11$15,223
SymbicortBudesonide/Formoterol Fumarate26$9,861
Breo ElliptaFluticasone/Vilanterol17$6,943
Omeprazole375$6,426
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$5,982
Losartan Potassium617$4,921

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaBreztri Aerosphere, Farxiga, Symbicort$318$67,28585 claims
PfizerEliquis$109$63,92050 claims
Boehringer IngelheimJardiance$66$44,96135 claims
Johnson & JohnsonXarelto$21$27,83919 claims
MerckJanuvia$22$15,22311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →